

Jai Rautela

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4432586/publications.pdf>

Version: 2024-02-01

20
papers

1,718
citations

686830

13
h-index

794141

19
g-index

21
all docs

21
docs citations

21
times ranked

2702
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. <i>Nature Immunology</i> , 2017, 18, 1004-1015.	7.0	504
2	The cancerâ€“natural killer cell immunity cycle. <i>Nature Reviews Cancer</i> , 2020, 20, 437-454.	12.8	308
3	CIS is a potent checkpoint in NK cellâ€“mediated tumor immunity. <i>Nature Immunology</i> , 2016, 17, 816-824.	7.0	289
4	IL-15 signaling in NK cell cancer immunotherapy. <i>Current Opinion in Immunology</i> , 2017, 44, 1-6.	2.4	102
5	Mesenchymal stromal cell apoptosis is required for their therapeutic function. <i>Nature Communications</i> , 2021, 12, 6495.	5.8	91
6	Cell cycle progression dictates the requirement for BCL2 in natural killer cell survival. <i>Journal of Experimental Medicine</i> , 2017, 214, 491-510.	4.2	66
7	IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos. <i>Blood</i> , 2018, 132, 2166-2178.	0.6	65
8	Therapeutic blockade of activin-A improves NK cell function and antitumor immunity. <i>Science Signaling</i> , 2019, 12, .	1.6	64
9	NK cellâ€“derived GM-CSF potentiates inflammatory arthritis and is negatively regulated by CIS. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	60
10	Harnessing Natural Killer Immunity in Metastatic SCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1507-1521.	0.5	50
11	Drug target validation in primary human natural killer cells using CRISPR RNP. <i>Journal of Leukocyte Biology</i> , 2020, 108, 1397-1408.	1.5	27
12	Molecular insight into targeting the NK cell immune response to cancer. <i>Immunology and Cell Biology</i> , 2018, 96, 477-484.	1.0	26
13	Therapeutic inhibition of the SRC-kinase HCK facilitates T cell tumor infiltration and improves response to immunotherapy. <i>Science Advances</i> , 2022, 8, .	4.7	16
14	Quantifying NK cell growth and survival changes in response to cytokines and regulatory checkpoint blockade helps identify optimal culture and expansion conditions. <i>Journal of Leukocyte Biology</i> , 2019, 105, 1341-1354.	1.5	11
15	Recipient BCL2 inhibition and NK cell ablation form part of a reduced intensity conditioning regime that improves allo-bone marrow transplantation outcomes. <i>Cell Death and Differentiation</i> , 2019, 26, 1516-1530.	5.0	10
16	miR17-92 restrains pro-apoptotic BIM to ensure survival of haematopoietic stem and progenitor cells. <i>Cell Death and Differentiation</i> , 2020, 27, 1475-1488.	5.0	9
17	BCL-XL antagonism selectively reduces neutrophil life span within inflamed tissues without causing neutropenia. <i>Blood Advances</i> , 2021, 5, 2550-2562.	2.5	9
18	Hhex Directly Represses BIM-Dependent Apoptosis to Promote NK Cell Development and Maintenance. <i>Cell Reports</i> , 2020, 33, 108285.	2.9	7

#	ARTICLE	IF	CITATIONS
19	Generation of novel Id2 and E2-2, E2A and HEB antibodies reveals novel Id2 binding partners and species-specific expression of E-proteins in NK cells. <i>Molecular Immunology</i> , 2019, 115, 56-63.	1.0	3
20	Loss-of-Function in SMAD4 Might Not Be Critical for Human Natural Killer Cell Responsiveness to TGF- β 2. <i>Frontiers in Immunology</i> , 2019, 10, 904.	2.2	0